Drucker, Daniel J.

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 3,896

Biology of Incretins: GLP-1 and GIP

Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 3,639

The biology of incretin hormones

Drucker, D. J. (2006) · Cell Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 2,210

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Drucker, D. J. (2018) · Cell Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 2,170

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 1,868

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 1,500

Normalization of obesity-associated insulin resistance through immunotherapy

Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine

Adipokines, Inflammation, and Metabolic DiseasesT-cell and B-cell Immunology

Cited by 1,370

FTO Obesity Variant Circuitry and Adipocyte Browning in Humans

Claussnitzer, M., Dankel, S. N., Kim, K.-H., Quon, G., Meuleman, W., Haugen, C., Glunk, V., Sousa, I. S., Beaudry, J. L., Puviindran, V., et al. (2015) · New England Journal of Medicine

Adipose Tissue and MetabolismGenetic Associations and Epidemiology

Cited by 1,332

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 1,070

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation

Diabetes Treatment and ManagementCardiac Ischemia and Reperfusion

Cited by 1,057

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y. D., et al. (2011) · Nature Medicine

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 922

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 903

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine

Neuroscience and Neuropharmacology ResearchNeuropeptides and Animal Physiology

Cited by 851

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 793

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 696

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology

Thyroid Disorders and TreatmentsDiabetes Treatment and Management

Cited by 672

The Cardiovascular Biology of Glucagon-like Peptide-1

Drucker, D. J. (2016) · Cell Metabolism

Diabetes Treatment and ManagementCardiovascular Disease and Adiposity

Cited by 665

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 645

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 641

Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis

Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 589

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 582

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 577

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes

Cardiac Ischemia and ReperfusionDiabetes Treatment and Management

Cited by 575

GLP-1 receptor activation and epac2 link atrial natriuretic peptide secretion to control of blood pressure

Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 514